This was a prospective observational study conducted between 2017 and 2019. The study population was matched against a historical cohort of patients treated between 2012 and 2018 who were treated with only ADT and radiotherapy. The primary endpoints were PSA less than 0.1 at 6 months. The secondary endpoints included PSA less than 0.1 at 12 months, testosterone less than 0.7 at 6 and 12 months, and toxicity profiles.
The patient cohort is shown in Figure 1, and the treatment protocol is shown in figure 2. All important clinical data are shown in table 1.
Figure 1 –
Figure 2-
Table 1 –
Figure 3 shows the percentage of patients with PSA less than 0.1 and testosterone less than 0.7 for the two patient subgroups. It is clearly seen that a higher percentage of patients in the abiraterone/enzalutamide +ADT+radiotherapy subgroup had PSA of less than 0.1 and testosterone of less than 0.7. This was consistent across all time points.
Figure 3 - PSA and testosterone results:
Figure 4 shows the toxicity profile in both subgroups. This includes genitourinary, gastrointestinal, hormonal and liver enzyme dysfunction rates.
Figure 4 – Toxicity profiles:
The authors concluded that the combination treatment of abiraterone or enzalutamide with ADT and radiotherapy can induce a more pronounced PSA response at 6 and 12 months in node-positive prostate cancer disease. Importantly, there was no significant increase in acute and late toxicities in the investigated cohort. However, despite these promising results, it still needs to be determined if this will ultimately result in superior survival outcomes as well.
Presented by: Mark Tan, MD, National Cancer Center, Singapore
Written By: Hanan Goldberg, MD, Urology Department, SUNY Upstate Medical University, Syracuse, NY, USA @GoldbergHanan at the 2020 Genitourinary Cancers Symposium, ASCO GU #GU20, February 13-15, 2020, San Francisco, California
Figure 1 –
Figure 2-
Table 1 –
Figure 3 shows the percentage of patients with PSA less than 0.1 and testosterone less than 0.7 for the two patient subgroups. It is clearly seen that a higher percentage of patients in the abiraterone/enzalutamide +ADT+radiotherapy subgroup had PSA of less than 0.1 and testosterone of less than 0.7. This was consistent across all time points.
Figure 3 - PSA and testosterone results:
Figure 4 shows the toxicity profile in both subgroups. This includes genitourinary, gastrointestinal, hormonal and liver enzyme dysfunction rates.
Figure 4 – Toxicity profiles:
The authors concluded that the combination treatment of abiraterone or enzalutamide with ADT and radiotherapy can induce a more pronounced PSA response at 6 and 12 months in node-positive prostate cancer disease. Importantly, there was no significant increase in acute and late toxicities in the investigated cohort. However, despite these promising results, it still needs to be determined if this will ultimately result in superior survival outcomes as well.
Presented by: Mark Tan, MD, National Cancer Center, Singapore
Written By: Hanan Goldberg, MD, Urology Department, SUNY Upstate Medical University, Syracuse, NY, USA @GoldbergHanan at the 2020 Genitourinary Cancers Symposium, ASCO GU #GU20, February 13-15, 2020, San Francisco, California